Stability of blood eosinophils in patients with chronic obstructive pulmonary disease and in control subjects, and the impact of sex, age, smoking, and baseline counts

American Journal of Respiratory and Critical Care Medicine

Volumn 195, Issue 10, 2017, Pages 1402-1404

  Oshagbemi, Olorunfemi A ^a,b,c,d   Burden, Andrea M ^a,b,c   Braeken, Dionne C W ^a,c,d   Henskens, Yvonne ^a   Wouters, Emiel F M ^a,d   Driessen, Johanna H M ^a,b,c   Maitland Van Der Zee, Anke H ^c,e   De Vries, Frank ^a,b,c,f   Franssen, Frits M E ^a,d  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d CIRO   (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BIOLOGICAL MARKER; CORTICOSTEROID; LONG ACTING DRUG; MUSCARINIC RECEPTOR BLOCKING AGENT; XANTHINE DERIVATIVE;

ADULT; AGED; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; EOSINOPHIL COUNT; EOSINOPHIL STABILITY; EOSINOPHILIA; FEMALE; FOLLOW UP; FRACTURE; GROUPS BY AGE; HEMATOLOGICAL PARAMETERS; HUMAN; HUMAN CELL; LETTER; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PRESCRIPTION; PRIORITY JOURNAL; SEX DIFFERENCE; SMOKING; TREATMENT RESPONSE; VERY ELDERLY; AGE; BLOOD; CASE CONTROL STUDY; CYTOLOGY; EOSINOPHIL; KAPLAN MEIER METHOD; LYMPHOCYTE COUNT; MIDDLE AGED;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DISEASE PROGRESSION; EOSINOPHILIA; EOSINOPHILS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEX FACTORS; SMOKING;

EID: 85019863797     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201701-0009LE     Document Type: Letter

References (9)

1. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Am J Respir Crit Care Med 2017;195:557-582.
2. Crim C, Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Willits LR, Yates JC, Vestbo J. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009;34:641-647.
3. Watz H, Tetzlaff K, Wouters EF, Kirsten A, Magnussen H, Rodriguez-Roisin R, Vogelmeier C, Fabbri LM, Chanez P, Dahl R, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med 2016;4:390-398.
4. Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 2015;3:435-442.
5. Vedel-Krogh S, Nielsen SF, Lange P, Vestbo J, Nordestgaard BG. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease: the Copenhagen General Population Study. Am J Respir Crit Care Med 2016;193:965-974.
6. Wedzicha JA. Eosinophils as biomarkers of chronic obstructive pulmonary disease exacerbation risk: maybe just for some? Am J Respir Crit Care Med 2016;193:937-938.
7. Kreindler JL, Watkins ML, Lettis S, Tal-Singer R, Locantore N. Effect of inhaled corticosteroids on blood eosinophil count in steroid-naïve patients with COPD. BMJ Open Respir Res 2016;3:e000151.
8. Mathur SK, Schwantes EA, Jarjour NN, Busse WW. Age-related changes in eosinophil function in human subjects. Chest 2008;133:412-419.
9. Singh D, Kolsum U, Brightling CE, Locantore N, Agusti A, Tal-Singer R; ECLIPSE Investigators. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J 2014;44:1697-1700.